Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2013

01-07-2013 | Author’s reply

Reply to Ozkan et al.: a role of elastography using maximum fat-to-lesion ratio for the diagnosis of breast lesions

Authors: Katsumi Ikeda, Yoshinari Ogawa

Published in: Breast Cancer | Issue 3/2013

Login to get access

Excerpt

Dear Editor …
Metadata
Title
Reply to Ozkan et al.: a role of elastography using maximum fat-to-lesion ratio for the diagnosis of breast lesions
Authors
Katsumi Ikeda
Yoshinari Ogawa
Publication date
01-07-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0371-0

Other articles of this Issue 3/2013

Breast Cancer 3/2013 Go to the issue

Original Article

Identification of candidates for postmastectomy radiotherapy in patients with pT3N0M0 breast cancer

Original Article

Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens

Original Article

Influence of the in situ component in 389 infiltrating ductal breast carcinomas

Letter to the Editor

Measuring of the maximum fat lesion ratio

Original Article

The thrombin inhibitor, argatroban, inhibits breast cancer metastasis to bone

Original Article

The role of chemoradiotherapy in patients with unresectable T4 breast tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits